

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number		10/635,807
Filing Date		August 5, 2003
First Named Inventor		RUBENSTEIN, EDWARD
Art Unit		Unassigned
Examiner Name		Unassigned
Attorney Docket Number		018050-000140US
Total Number of Pages in This Submission		

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard PTO/SB/08A and /08B Form 0 Reference Copies
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP	
	James M. Heslin	Reg. No. 29,541
Signature		
Date	8/26/03	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Edward Masinas		
Signature		Date	08-27-03

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 018050-000140US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

08-27-03
TOWNSEND and TOWNSEND and CREW LLP
Edward Masinas
Edward Masinas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

EDWARD RUBENSTEIN et al.

Application No.: 10/635,807

Filed: August 5, 2003

For: INTERNALLY POWERED CSF
PUMP SYSTEMS AND METHODS

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application Nos. 09/654,967 or 08/901,023, filed 09/05/00 and 07/25/97 (Attorney Docket Nos. 018050-000120US and 018050-000110US, respectively). It is requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



James M. Heslin
Reg. No. 29,541

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JMH:bjl
60026962 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

3

of

Complete if Known

Application Number	10/635,807
Filing Date	August 5, 2003
First Named Inventor	RUBENSTEIN, EDWARD, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	018050-000140US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	A	3,654,932	04/1972	Newkirk et al.	
	B	3,864,259	02/1975	Newhart	
	C	3,886,948	06/03/75	Hakim	
	D	4,156,422	05/29/79	Hildebrandt et al.	
	E	4,261,341	04//1981	Hakim et al.	
	F	4,375,816	03/08/83	Labianca	
	G	4,560,375	12/24/85	Schulte et al.	
	H	4,598,579	07/08/86	Cummings et al.	
	I	4,605,395	08/12/86	Rose et al.	
	J	4,610,658	09/1986	Buchwald et al.	
	K	4,673,384	06/16/87	Marion	
	L	4,675,003	06/1987	Hooven	
	M	4,681,559	07/1987	Hooven	
	N	4,713,065	12/1987	Koot	
	O	4,933,156	06/12/90	Quay et al.	
	P	4,950,232	08/21/90	Ruzicka et al.	
	Q	5,039,511	08/13/91	Quay	
	R	5,069,663	12/1991	Sussman	
	S	5,167,615	12/1992	East et al.	
	T	5,334,315	08/02/94	Matkovich et al.	
	U	5,336,166	08/09/94	Sierra	
	V	5,368,556	11/1994	Lecuyer	
	W	5,385,541	01/31/95	Kirsch et al.	
	X	5,387,188	02/07/95	Watson	

Examiner
Signature

Date


Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

60026962 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

5

of

Complete if Known

Application Number	10/635,807
Filing Date	August 5, 2003
First Named Inventor	RUBENSTEIN, EDWARD, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	018050-000140US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AG	Adams et al., "Disturbances of cerebrospinal fluid circulation, including hydrocephalus and meningeal reactions," <i>Principles of Neurology</i> , Fourth Edition, Chapter 30, 1989, pp. 501-502.	
	AH	Adams, R.D. et al., "Symptomatic occult hydrocephalus with 'normal' cerebrospinal-fluid pressure" <i>The New England Journal of Medicine</i> , Vol. 273, No. 3, pages 117-126 (July 15, 1965).	
	AI	Appenzeller, Otto & Salmon, James H., "Treatment of parenchymatous degeneration of the brain by ventriculo-atrial shunting of the cerebrospinal fluid, <i>Journal of Neurosurgery</i> , Volume XXVI, pages 478-482, (January-June 1967).	
	AJ	Arai et al., "Tau in cerebrospinal fluid: a potential diagnostic marker," <i>Ann. Neurology</i> , vol. 38, 1995, pp. 649-652.	
	AK	Bannister, Roger, et al., "Isotope encephalography in the diagnosis of dementia due to communicating hydrocephalus" <i>The Lancet</i> , pgs. 1014-1017, (November 11, 1967).	
	AL	Barnett et al., "Normal pressure hydrocephalus in children and young adults" <i>Neurosurgery</i> (1987) 20(6):904-907.	
	AM	Boon et al., "Does CSF outflow resistance predict the response to shunting in patients with normal pressure hydrocephalus?" <i>Acta Neurochir.</i> (1998) 71:331-333.	
	AN	Boon et al., "Dutch normal-pressure hydrocephalus study: Prediction of outcome after shunting by resistance to outflow of cerebrospinal fluid" <i>J. Neurosurg.</i> (1997) 87:687-693.	
	AO	Bush et al., "Beta A-4 amyloid protein and its precursor in Alzheimer's disease," <i>Pharmac. Tera.</i> , Vol. 56, 1992, pp. 97-117.	

Examiner
Signature

Date


Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

60026962 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page **6**

of

Complete if Known

Applicati n Number	10/635,807
Filing Date	August 5, 2003
First Named Inventor	RUBENSTEIN, EDWARD, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	018050-000140US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AP	Chen, I.H. et al., "Effectiveness of shunting in patients with normal pressure hydrocephalus predicted by temporary, controlled-resistance, continuous lumbar drainage: a pilot study," <i>Journal of Neurology, Neurosurgery, and Psychiatry</i> , 1994, S/1430-1432.						
	AQ	Clarfield, "Normal-pressure hydrocephalus: Saga or swamp?" <i>JAMA</i> (1989) 262(18):2592-2593.						
	AR	Damasceno et al., "The predictive value of cerebrospinal fluid tap-test in normal pressure hydrocephalus" <i>Arq. Neurosiquiatr.</i> (1997) 55(2):179-185.						
	AS	Friedland, "Normal-pressure hydrocephalus and the saga of the treatable dementias" <i>JAMA</i> (1989) 262(18):2577-2581.						
	AT	Golomb et al., "Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response" <i>J. Neurol. Neurosurg. Psych.</i> (2000) 68:778-781.						
	AU	Graff-Radford et al., "Normal-pressure hydrocephalus" <i>Neurol.</i> (1986) 43:940-942.						
	AV	Gustafson et al., "Recovery in hydrocephalic dementia after shunt operation" <i>J. Neurol. Neurosurg. Psych.</i> (1978) 41:940-947.						
	AW	Hakim et al., "The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics" <i>J. Neurol. Sci.</i> (1965) 2:307-327.						
	AX	Holodny et al., "Focal dilation and paradoxical collapse of cortical fissures and sulci in patients with normal-pressure hydrocephalus" <i>J. Neurosurg.</i> (1998) 89:742-747.						
	AY	Kaye et al., "Plasticity in the aging brain" <i>Arch Neurol.</i> (1990) 47:1336-1341.						
	AZ	Ko et al., "Cerebrospinal fluid control system" Proceedings of the IEEE, Vol. 76, No. 9, pp. 1226-1235, September 1988.						
	BA	Martinez et al., "Relationship of interleukin-1 beta and beta ₂ -microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type," <i>J. Neuroimmunology</i> , Vol. 48, 1993, pp 235-240.						

Examiner
SignatureDate
Considered


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

60026962 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

7

of

Complete if Known

Applicati n Number	10/635,807
Filing Dat	August 5, 2003
First Named Inventor	RUBENSTEIN, EDWARD, et. al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	018050-000140US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁹
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	BB	Mataró et al., "Cognitive changes after cerebrospinal fluid shunting in young adults with spina bifida and assumed arrested hydrocephalus" <i>J. Neurol. Neurosurg. Psych.</i> (2000) 68:615-621.						
	BC	Mogilner et al., "Hydorcephalus: Does coexistent Alzheimer's disease affect outcome?" <i>Poster Presentation from AANS 1999 New Orleans</i> , http://cnshome.org/abstrats , 2 pages total.						
	BD	Nakamura et al., "Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease," <i>Ann. Neurology</i> , Vol. 36, 1994, pp. 903-911.						
	BE	Ono et al., "Formation of amyloid-like substance from beta-2-microglobulin in vitro. Role of serum amyloid P component: a preliminary study," <i>Nephron</i> . Vol. 66, 1994, pp. 404-407.						
	BF	Salmon, James H., "Senile and presenile dementia" <i>Geriatrics</i> (December 1969) 24 (12) : 67-72.						
	BG	Shenkin et al., "Ventricular shunting for relief of senile symptoms" <i>JAMA</i> (1973) 225(12):1486-1489.						
	BH	Skinhøj, Erik, "Determination of regional cerebral bloodflow in man" Head injury conference proceedings, held at the University of Chicago Center for Continuing Education with Joseph P. Evans as host. No. 34, pgs. 431-438.						
	BI	Vanneste et al., "Shunting normal-pressure hyrocephalus: Do the benefits outweigh the risks?" <i>Neurol.</i> (1992) 42:54-59.						
	BJ	Vorstrup et al., "Cerebral blod flow in patients with normal-pressure hydrocephalus before and after shunting" <i>J. Neurol.</i> (1987) 66:379-387.						
	BK	Williams et al., "Evaluation of shunt function in patients who are never better, or better than worse after shunt surgery for NPH" <i>Acta Neurochir.</i> (1998) 71:368-370.						
	BL	Williams et al., "Comparison of Pcsf monitoring and controlled CSF drainage diagnose normal pressure hydrocephalus" <i>Acta Neurochir.</i> (1998) 71:328-330.						

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
60026962 v1

